down arrow

Abeona Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00289Y2063
USD
5.41
0.11 (2.08%)

Dec 24

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

5.335.48

52 Week

3.937.54
Valuation
Technical
Day's Volume

CASH

709.59 k

Shareholding (Mar 2025)

FII

6.57%

Held by 23 FIIs

DII

79.58%

Held by 11 DIIs

Promoter

6.24%

How big is Abeona Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Abeona Therapeutics, Inc. has a market capitalization of 306.94 million and reported net sales of 0.00 million with a net profit of -44.18 million over the last four quarters. Shareholder's funds are 44.03 million, and total assets are 108.93 million as of Dec 24.

As of Jun 18, Abeona Therapeutics, Inc. has a market capitalization of 306.94 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -44.18 million.<BR><BR>As of Dec 24, the Shareholder's Funds amount to 44.03 million, and the Total Assets are reported at 108.93 million.

Read More

What does Abeona Therapeutics, Inc. do?

22-Jun-2025

Abeona Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare genetic diseases. It has a market cap of approximately $306.94 million and reported a net profit loss of $12 million as of March 2025.

Overview: <BR>Abeona Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -12 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 306.94 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.56 <BR>Return on Equity: -164.21% <BR>Price to Book: 7.41<BR><BR>Contact Details: <BR>Address: 1330 Avenue of the Americas Fl 33, NEW YORK NY: 10019-5442 <BR>Tel: 1 646 8134701 <BR>Fax: 1 302 6555049 <BR>Website: https://abeonatherapeutics.com/

Read More

Who are in the management team of Abeona Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Abeona Therapeutics, Inc. includes Ms. Christine Silverstein (Director), Mr. Paul Mann (Independent Director), and Dr. Todd Wider (Independent Director).

As of March 2022, the management team of Abeona Therapeutics, Inc. includes Ms. Christine Silverstein, who serves as a Director, Mr. Paul Mann, who is an Independent Director, and Dr. Todd Wider, also an Independent Director.

Read More

Is Abeona Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of August 12, 2024, Abeona Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify" due to negative financial metrics, including a Price to Book Value of 8.33 and a negative ROE of -164.21%, significantly underperforming compared to peers like Talaris Therapeutics and Protalix Biotherapeutics.

As of 12 August 2024, the valuation grade for Abeona Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued, particularly given its negative financial metrics. The Price to Book Value stands at 8.33, while the EV to EBIT and EV to EBITDA ratios are at -4.03 and -4.27, respectively, reflecting a lack of profitability.<BR><BR>In comparison to its peers, Abeona Therapeutics shows a stark contrast with Talaris Therapeutics, which has an EV to EBITDA of -2.2059, and Protalix Biotherapeutics, which is rated attractive with a P/E of 27.9073. The negative ROE of -164.21% further emphasizes the company's struggles, making it difficult to justify its current price of 5.81, especially as it has underperformed against the S&P 500 over various time frames.

Read More

Is Abeona Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Abeona Therapeutics, Inc. has a mildly bullish trend, supported by daily moving averages, despite underperforming the S&P 500 with returns of -16.44% over the past week and -18.38% over the past month.

As of 12 September 2025, the technical trend for Abeona Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages indicating mild bullishness, while the weekly MACD and KST suggest a mildly bearish outlook. The monthly MACD and Dow Theory, however, are mildly bullish, providing some support to the overall stance. <BR><BR>In terms of performance, Abeona has underperformed the S&P 500 over the past week and month, with returns of -16.44% and -18.38%, respectively, compared to the S&P's gains of 1.05% and 2.33%. Over longer periods, the stock has shown mixed results, with a YTD return of 1.26% versus the S&P's 12.22%, and a 1-year return of 3.49% compared to 17.14% for the index.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 344 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.26

stock-summary
Return on Equity

38.57%

stock-summary
Price to Book

2.10

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
109 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.52%
0%
-2.52%
6 Months
-7.68%
0%
-7.68%
1 Year
-4.75%
0%
-4.75%
2 Years
8.85%
0%
8.85%
3 Years
115.54%
0%
115.54%
4 Years
-40.12%
0%
-40.12%
5 Years
-87.49%
0%
-87.49%

Abeona Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
6.96%
EBIT Growth (5y)
-4.49%
EBIT to Interest (avg)
-26.41
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.56
Sales to Capital Employed (avg)
0.18
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
76.21%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.33
EV to EBIT
-4.03
EV to EBITDA
-4.27
EV to Capital Employed
-12.08
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-164.21%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 9 Schemes (7.61%)

Foreign Institutions

Held by 23 Foreign Institutions (6.57%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 1,006.67% vs -29.03% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.00",
          "val2": "-18.90",
          "chgp": "-16.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "1.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.40",
          "val2": "7.20",
          "chgp": "-175.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "108.80",
          "val2": "-12.00",
          "chgp": "1,006.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-56,980.00%",
          "val2": "0.00%",
          "chgp": "-5,698.00%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 150.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -17.53% vs -36.52% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "3.50",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-61.30",
          "val2": "-45.00",
          "chgp": "-36.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.20",
          "val2": "0.40",
          "chgp": "950.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.80",
          "val2": "-9.60",
          "chgp": "91.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-63.70",
          "val2": "-54.20",
          "chgp": "-17.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-13,771.40%",
          "chgp": "1,377.14%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.40
0.00
Operating Profit (PBDIT) excl Other Income
-22.00
-18.90
-16.40%
Interest
1.00
1.00
Exceptional Items
-5.40
7.20
-175.00%
Consolidate Net Profit
108.80
-12.00
1,006.67%
Operating Profit Margin (Excl OI)
-56,980.00%
0.00%
-5,698.00%
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 1,006.67% vs -29.03% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
3.50
-100.00%
Operating Profit (PBDIT) excl Other Income
-61.30
-45.00
-36.22%
Interest
4.20
0.40
950.00%
Exceptional Items
-0.80
-9.60
91.67%
Consolidate Net Profit
-63.70
-54.20
-17.53%
Operating Profit Margin (Excl OI)
0.00%
-13,771.40%
1,377.14%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 150.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -17.53% vs -36.52% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Abeona Therapeutics, Inc. stock-summary
stock-summary
Abeona Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
Company Coordinates stock-summary
Company Details
1330 Avenue of the Americas Fl 33 , NEW YORK NY : 10019-5442
stock-summary
Tel: 1 646 8134701
stock-summary
https://abeonatherapeutics.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."